Literature DB >> 26819670

Synthesis and Evaluation of Oxyguanidine Analogues of the Cysteine Protease Inhibitor WRR-483 against Cruzain.

Brian D Jones1, Anna Tochowicz2, Yinyan Tang3, Michael D Cameron4, Laura-Isobel McCall5, Ken Hirata6, Jair L Siqueira-Neto5, Sharon L Reed7, James H McKerrow2, William R Roush1.   

Abstract

A series of oxyguanidine analogues of the cysteine protease inhibitor WRR-483 were synthesized and evaluated against cruzain, the major cysteine protease of the protozoan parasite Trypanosoma cruzi. Kinetic analyses of these analogues indicated that they have comparable potency to previously prepared vinyl sulfone cruzain inhibitors. Co-crystal structures of the oxyguanidine analogues WRR-666 (4) and WRR-669 (7) bound to cruzain demonstrated different binding interactions with the cysteine protease, depending on the aryl moiety of the P1' inhibitor subunit. Specifically, these data demonstrate that WRR-669 is bound noncovalently in the crystal structure. This represents a rare example of noncovalent inhibition of a cysteine protease by a vinyl sulfone inhibitor.

Entities:  

Keywords:  Chagas’ disease; X-ray crystallography; cysteine protease inhibitor; kinetics; noncovalent inhibitor; vinyl sulfone

Year:  2015        PMID: 26819670      PMCID: PMC4716606          DOI: 10.1021/acsmedchemlett.5b00336

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  24 in total

1.  Potent second generation vinyl sulfonamide inhibitors of the trypanosomal cysteine protease cruzain.

Authors:  W R Roush; J Cheng; B Knapp-Reed; A Alvarez-Hernandez; J H McKerrow; E Hansell; J C Engel
Journal:  Bioorg Med Chem Lett       Date:  2001-10-22       Impact factor: 2.823

2.  Cost-effectiveness of Chagas disease interventions in latin america and the Caribbean: Markov models.

Authors:  Leslie S Wilson; Arthur M Strosberg; Kimberly Barrio
Journal:  Am J Trop Med Hyg       Date:  2005-11       Impact factor: 2.345

Review 3.  Cruzain : the path from target validation to the clinic.

Authors:  Mohammed Sajid; Stephanie A Robertson; Linda S Brinen; James H McKerrow
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

Review 4.  Chagas disease.

Authors:  Anis Rassi; Anis Rassi; José Antonio Marin-Neto
Journal:  Lancet       Date:  2010-04-17       Impact factor: 79.321

5.  NG-hydroxyguanidines from primary amines.

Authors:  Nathaniel I Martin; Joshua J Woodward; Michael A Marletta
Journal:  Org Lett       Date:  2006-08-31       Impact factor: 6.005

6.  Oxyguanidines: application to non-peptidic phenyl-based thrombin inhibitors.

Authors:  Bruce Tomczuk; Tianbao Lu; Richard M Soll; Cynthia Fedde; Aihua Wang; Larry Murphy; Carl Crysler; Malini Dasgupta; Stephen Eisennagel; John Spurlino; Roger Bone
Journal:  Bioorg Med Chem Lett       Date:  2003-04-17       Impact factor: 2.823

7.  In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi.

Authors:  Yen Ting Chen; Linda S Brinen; Iain D Kerr; Elizabeth Hansell; Patricia S Doyle; James H McKerrow; William R Roush
Journal:  PLoS Negl Trop Dis       Date:  2010-09-14

8.  Structure-activity relationships for inhibition of cysteine protease activity and development of Plasmodium falciparum by peptidyl vinyl sulfones.

Authors:  Bhaskar R Shenai; Belinda J Lee; Alejandro Alvarez-Hernandez; Pek Y Chong; Cory D Emal; R Jeffrey Neitz; William R Roush; Philip J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

9.  Use of recombinant Entamoeba histolytica cysteine proteinase 1 to identify a potent inhibitor of amebic invasion in a human colonic model.

Authors:  Samuel G Meléndez-López; Scott Herdman; Ken Hirata; Min-Ho Choi; Youngchool Choe; Charles Craik; Conor R Caffrey; Elisabeth Hansell; Bibiana Chávez-Munguía; Yen Ting Chen; William R Roush; James McKerrow; Lars Eckmann; Jianhua Guo; Samuel L Stanley; Sharon L Reed
Journal:  Eukaryot Cell       Date:  2007-05-18

Review 10.  Current and developing therapeutic agents in the treatment of Chagas disease.

Authors:  Werner Apt
Journal:  Drug Des Devel Ther       Date:  2010-09-24       Impact factor: 4.162

View more
  5 in total

1.  Design of Gallinamide A Analogs as Potent Inhibitors of the Cysteine Proteases Human Cathepsin L and Trypanosoma cruzi Cruzain.

Authors:  Paul D Boudreau; Bailey W Miller; Laura-Isobel McCall; Jehad Almaliti; Raphael Reher; Ken Hirata; Thu Le; Jair L Siqueira-Neto; Vivian Hook; William H Gerwick
Journal:  J Med Chem       Date:  2019-10-04       Impact factor: 7.446

2.  Peptidomimetic Vinyl Heterocyclic Inhibitors of Cruzain Effect Antitrypanosomal Activity.

Authors:  Bala C Chenna; Linfeng Li; Drake M Mellott; Xiang Zhai; Jair L Siqueira-Neto; Claudia Calvet Alvarez; Jean A Bernatchez; Emily Desormeaux; Elizabeth Alvarez Hernandez; Jana Gomez; James H McKerrow; Jorge Cruz-Reyes; Thomas D Meek
Journal:  J Med Chem       Date:  2020-03-17       Impact factor: 7.446

3.  On the intrinsic reactivity of highly potent trypanocidal cruzain inhibitors.

Authors:  Vinicius Bonatto; Pedro Henrique Jatai Batista; Lorenzo Cianni; Daniela De Vita; Daniel G Silva; Rodrigo Cedron; Daiane Y Tezuka; Sérgio de Albuquerque; Carolina Borsoi Moraes; Caio Haddad Franco; Jerônimo Lameira; Andrei Leitão; Carlos A Montanari
Journal:  RSC Med Chem       Date:  2020-09-09

Review 4.  Cysteine proteases in protozoan parasites.

Authors:  Jair L Siqueira-Neto; Anjan Debnath; Laura-Isobel McCall; Jean A Bernatchez; Momar Ndao; Sharon L Reed; Philip J Rosenthal
Journal:  PLoS Negl Trop Dis       Date:  2018-08-23

5.  The novel BET inhibitor UM-002 reduces glioblastoma cell proliferation and invasion.

Authors:  Anna M Jermakowicz; Matthew J Rybin; Robert K Suter; Jann N Sarkaria; Zane Zeier; Yangbo Feng; Nagi G Ayad
Journal:  Sci Rep       Date:  2021-12-03       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.